| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/23/2023 | 226.09% | HC Wainwright & Co. | $48 → $30 | Maintains | Buy |
| 10/02/2023 | 63.04% | RBC Capital | $25 → $15 | Maintains | Sector Perform |
| 09/19/2023 | 421.74% | HC Wainwright & Co. | → $48 | Reiterates | Buy → Buy |
| 08/09/2023 | 171.74% | Oppenheimer | $30 → $25 | Maintains | Perform |
| 08/08/2023 | 421.74% | HC Wainwright & Co. | → $48 | Reiterates | Buy → Buy |
| 08/08/2023 | 171.74% | RBC Capital | → $25 | Reiterates | Sector Perform → Sector Perform |
| 08/08/2023 | 356.52% | JMP Securities | $65 → $42 | Maintains | Market Outperform |
| 08/08/2023 | 95.65% | Jefferies | $49 → $18 | Downgrades | Buy → Hold |
| 05/11/2023 | 226.09% | Oppenheimer | $50 → $30 | Reiterates | Perform → Perform |
| 05/09/2023 | 258.7% | RBC Capital | $48 → $33 | Maintains | Sector Perform |
| 05/09/2023 | 421.74% | HC Wainwright & Co. | $68 → $48 | Maintains | Buy |
| 05/09/2023 | 606.52% | JMP Securities | $82 → $65 | Maintains | Outperform |
| 03/22/2023 | 486.96% | RBC Capital | → $54 | Reiterates | → Sector Perform |
| 02/09/2023 | 432.61% | SVB Leerink | → $49 | Reiterates | → Market Perform |
| 02/08/2023 | 845.65% | Piper Sandler | → $87 | Maintains | Overweight |
| 02/08/2023 | 552.17% | JP Morgan | $74 → $60 | Maintains | Neutral |
| 01/27/2023 | 432.61% | SVB Leerink | $50 → $49 | Maintains | Market Perform |
| 12/09/2022 | 508.7% | HC Wainwright & Co. | → $56 | Initiates Coverage On | → Buy |
| 11/22/2022 | 486.96% | RBC Capital | $65 → $54 | Maintains | Sector Perform |
| 08/10/2022 | 541.3% | Oppenheimer | $53 → $59 | Maintains | Perform |
| 08/09/2022 | 1389.13% | JMP Securities | $103 → $137 | Maintains | Market Outperform |
| 08/09/2022 | 617.39% | RBC Capital | $67 → $66 | Maintains | Sector Perform |
| 08/01/2022 | 476.09% | Oppenheimer | $45 → $53 | Maintains | Perform |
| 08/01/2022 | 443.48% | SVB Leerink | $44 → $50 | Maintains | Market Perform |
| 07/06/2022 | 573.91% | Evercore ISI Group | → $62 | Upgrades | In-Line → Outperform |
| 07/01/2022 | 628.26% | RBC Capital | $64 → $67 | Maintains | Sector Perform |
| 06/01/2022 | 323.91% | Evercore ISI Group | → $39 | Upgrades | Underperform → In-Line |
| 05/20/2022 | 389.13% | Oppenheimer | $70 → $45 | Maintains | Outperform |
| 05/19/2022 | 878.26% | Baird | $130 → $90 | Maintains | Outperform |
| 05/19/2022 | 1019.57% | JMP Securities | $114 → $103 | Maintains | Market Outperform |
| 05/19/2022 | 378.26% | SVB Leerink | $58 → $44 | Maintains | Market Perform |
| 05/12/2022 | 660.87% | Roth Capital | $101 → $70 | Maintains | Buy |
| 05/10/2022 | 1139.13% | JMP Securities | $116 → $114 | Maintains | Market Outperform |
| 05/10/2022 | 530.43% | SVB Leerink | $68 → $58 | Maintains | Market Perform |
| 05/10/2022 | 595.65% | RBC Capital | $72 → $64 | Maintains | Sector Perform |
| 02/09/2022 | 639.13% | SVB Leerink | $80 → $68 | Maintains | Market Perform |
| 01/13/2022 | 769.57% | SVB Leerink | $85 → $80 | Maintains | Market Perform |
| 11/24/2021 | 693.48% | Oppenheimer | $55 → $73 | Maintains | Perform |
| 11/23/2021 | 1160.87% | JMP Securities | $111 → $116 | Maintains | Market Outperform |
| 11/23/2021 | 823.91% | SVB Leerink | $92 → $85 | Maintains | Market Perform |
| 11/19/2021 | 682.61% | RBC Capital | $74 → $72 | Maintains | Sector Perform |
| 11/19/2021 | 1106.52% | JMP Securities | $121 → $111 | Maintains | Market Outperform |
| 11/08/2021 | 1215.22% | JMP Securities | $77 → $121 | Maintains | Market Outperform |
| 11/08/2021 | 900% | SVB Leerink | $55 → $92 | Maintains | Market Perform |
| 10/20/2021 | 704.35% | RBC Capital | $58 → $74 | Maintains | Sector Perform |
| 10/20/2021 | 736.96% | JMP Securities | $73 → $77 | Maintains | Market Outperform |
| 10/07/2021 | 932.61% | Jefferies | → $95 | Initiates Coverage On | → Buy |
| 09/09/2021 | 497.83% | SVB Leerink | → $55 | Initiates Coverage On | → Market Perform |
| 08/09/2021 | 443.48% | RBC Capital | $52 → $50 | Maintains | Sector Perform |
| 08/06/2021 | 443.48% | RBC Capital | $52 → $50 | Maintains | Sector Perform |
| 08/06/2021 | 736.96% | JMP Securities | $70 → $77 | Maintains | Market Outperform |
| 01/29/2021 | 497.83% | JP Morgan | $44 → $55 | Upgrades | Underweight → Neutral |
| 11/24/2020 | 226.09% | Evercore ISI Group | → $30 | Initiates Coverage On | → Underperform |
| 08/28/2020 | 1030.43% | Roth Capital | → $104 | Reinstates | → Buy |
| 08/26/2020 | 845.65% | Piper Sandler | → $87 | Initiates Coverage On | → Overweight |
| 07/27/2020 | 660.87% | JMP Securities | → $70 | Upgrades | Market Perform → Market Outperform |
| 03/17/2020 | 552.17% | Baird | → $60 | Upgrades | Neutral → Outperform |
| 11/22/2019 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 09/26/2019 | 519.57% | JP Morgan | $86 → $57 | Downgrades | Neutral → Underweight |
| 12/13/2018 | 769.57% | Berenberg | → $80 | Initiates Coverage On | → Buy |
What is the target price for Enanta Pharma (ENTA)?
The latest price target for Enanta Pharma (NASDAQ: ENTA) was reported by HC Wainwright & Co. on October 23, 2023. The analyst firm set a price target for $30.00 expecting ENTA to rise to within 12 months (a possible 226.09% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Enanta Pharma (ENTA)?
The latest analyst rating for Enanta Pharma (NASDAQ: ENTA) was provided by HC Wainwright & Co., and Enanta Pharma maintained their buy rating.
When is the next analyst rating going to be posted or updated for Enanta Pharma (ENTA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enanta Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enanta Pharma was filed on October 23, 2023 so you should expect the next rating to be made available sometime around October 23, 2024.
Is the Analyst Rating Enanta Pharma (ENTA) correct?
While ratings are subjective and will change, the latest Enanta Pharma (ENTA) rating was a maintained with a price target of $48.00 to $30.00. The current price Enanta Pharma (ENTA) is trading at is $9.20, which is out of the analyst's predicted range.